Regeneron Pharmaceuticals Inc (REGN) Gross Profit Margin starting from the third quarter 2026 to third quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket
 


Regeneron Pharmaceuticals Inc   (NASDAQ: REGN)


Regeneron Pharmaceuticals Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics



REGN Gross Profit Margin (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Revenue Change 36.27 %
Seq. Revenue Change 19.23 %
Revenue In Millions $5,115.80
Gross Profit Margin 88.79 %
Gross Profit Margin Total Ranking # 387
Gross Profit In Millions $4,542.20
Y / Y Gross Profit Change 30.77 %
Seq. Gross Profit Change 22.29 %


Commenting Third Quarter 2026 Gross Profit Margin
Regeneron Pharmaceuticals Inc Gross Profit grew by 22.29 % in Q3 sequentially to 4,542 millions, while Revenue increased by 19.23 %, this led to improvement in the company's Gross Profit Margin to 88.79 %, Gross Profit Margin remained below Regeneron Pharmaceuticals Inc average.


Observing third quarter 2026 results within Major Pharmaceutical Preparations industry 39 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 358 to 387.
Learn about Gross Margin
REGN's Gross Profit Margin third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 40
Healthcare Sector # 62
Overall # 384

Gross Profit Margin Statistics
High Average Low
98.26 % 93.77 % 83.61 %
(Dec 31 2018)   (Dec 31 2021)




Other Gross Profit Margin Profitability Ratios
REGN's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
REGN's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for REGN's Competitors
Gross Profit Margin Profit Margin for Regeneron Pharmaceuticals Inc 's Suppliers
Gross Profit Margin Profit Margin for REGN's Customers

You may also want to know
REGN's Annual Growth Rates REGN's Profitability Ratios REGN's Asset Turnover Ratio REGN's Dividend Growth
REGN's Roe REGN's Valuation Ratios REGN's Financial Strength Ratios REGN's Gross Profit Growth
REGN's Roa REGN's Inventory Turnover Ratio REGN's Growth Rates REGN's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2026 MRQ Gross ProfitSep 30 2026 MRQ Revenue
Protagonist Therapeutics inc   99.60 %$ 273.310  Millions$ 274.410  Millions
Lexicon Pharmaceuticals Inc   99.30 %$ 11.171  Millions$ 11.250  Millions
Verastem Inc   98.84 %$ 23.733  Millions$ 24.012  Millions
Travere Therapeutics Inc   98.72 %$ 221.696  Millions$ 224.563  Millions
Adc Therapeutics Sa  98.67 %$ 21.428  Millions$ 21.716  Millions
Corcept Therapeutics Inc  98.65 %$ 335.864  Millions$ 340.472  Millions
Ardelyx inc   96.44 %$ 123.116  Millions$ 127.655  Millions
Uniqure N v   95.46 %$ 4.960  Millions$ 5.196  Millions
Agios Pharmaceuticals Inc   95.44 %$ 52.860  Millions$ 55.385  Millions
Zevra Therapeutics Inc   95.25 %$ 35.962  Millions$ 37.756  Millions
Bridgebio Pharma Inc   94.21 %$ 332.721  Millions$ 353.171  Millions
Gyre Therapeutics Inc   94.09 %$ 30.987  Millions$ 32.934  Millions
Vanda Pharmaceuticals Inc   94.05 %$ 65.663  Millions$ 69.815  Millions
Axsome Therapeutics Inc   93.14 %$ 241.887  Millions$ 259.691  Millions
Tonix Pharmaceuticals Holding Corp   92.74 %$ 15.982  Millions$ 17.234  Millions
Urogen Pharma Ltd   91.57 %$ 81.499  Millions$ 89.001  Millions
Arcutis Biotherapeutics Inc   91.34 %$ 131.459  Millions$ 143.919  Millions
Roivant Sciences Ltd   90.47 %$ 31.774  Millions$ 35.121  Millions
Kiniksa Pharmaceuticals International Plc  90.29 %$ 258.211  Millions$ 285.970  Millions
Aurinia Pharmaceuticals Inc   90.08 %$ 75.393  Millions$ 83.699  Millions
Acadia Pharmaceuticals Inc   89.75 %$ 307.201  Millions$ 342.291  Millions
Mannkind Corporation  88.99 %$ 90.657  Millions$ 101.870  Millions
Regeneron Pharmaceuticals Inc   88.79 %$ 4,542.200  Millions$ 5,115.800  Millions
Beone Medicines Ltd   88.52 %$ 1,672.919  Millions$ 1,889.815  Millions
Xeris Biopharma Holdings Inc   88.41 %$ 94.796  Millions$ 107.225  Millions
United Therapeutics Corporation  88.10 %$ 733.400  Millions$ 832.500  Millions
Supernus Pharmaceuticals inc   88.09 %$ 199.753  Millions$ 226.771  Millions
Aclaris Therapeutics Inc   87.24 %$ 1.292  Millions$ 1.481  Millions
Ligand Pharmaceuticals Incorporated  87.04 %$ 68.541  Millions$ 78.746  Millions
Rhythm Pharmaceuticals Inc   86.79 %$ 79.962  Millions$ 92.128  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.